# NunaBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nunabio

- Industry: Biotechnology
- Headquarters: Newcastle upon Tyne, UK
- Website: www.nunabio.com/
- Total disclosed funding: $2.3M
- Latest round: Seed (Mar 7, 2023)
- Investors on record: 4

## About

Based in the UK, and founded in 2021 by Joe Hedley (CEO), Eimer Tuite (CSO) and Andrew Pike (CTO), Nuna Bio is a biotechnology company that uses advanced analytics to create personalized treatment solutions for complex diseases such as cancer, autoimmune disorders, and neurological disorders. NunaBio is developing an advanced method for DNA synthesis that will enable the manufacturing of oligonucleotides with precision and speed. Furthermore, the company's platform will enable the creation of entire genes and DNA segments of unfamiliar length without the use of plasmids or primers, which are currently limiting factors in the field of synthetic biology. In addition, the firm's technology can be applied to various fields in life sciences, such as gene therapy, T-cell manipulation, viral vector creation, diagnosis, hybridization capture, and targeted biomarker identification. In April 2026, NunaBio Ltd. raised GBP 6.5 million in venture funding led by Northstar Ventures, with participation from Ascension, Pioneer Group, HIT Capital, and Maven Capital Partners.

The company will use the May 2026 funding for synthetic deoxyribonucleic acid platform scale-up and industry partnership expansion.

## Funding rounds

- Seed, Mar 7, 2023, $2.3M — Northstar Ventures, Martlet Capital, Ascension, The Pioneer Group

## Investors

- Northstar Ventures (https://capitalatlas.ai/funds/northstar-ventures) — Seed
- Martlet Capital (https://capitalatlas.ai/funds/martlet-capital) — Seed
- Ascension (https://capitalatlas.ai/funds/ascension) — Seed
- The Pioneer Group — Seed